Luspatercept

• Phase 2 Study of Momelotinib in Combination with Luspatercept in Participants with Transfusion Dependent Myelofibrosis. Pending
  2024-518225-15-00 Phase II 4 countries Glaxosmithkline Research & Development Limited
• LUSPARA - Luspatercept in patients affected with rare inherited anemias Recruiting
  2024-520200-26-00 Phase II 2 countries Eurobloodnet Association
• Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to Myelodysplastic Syndromes with del5q refractory/resistant/intolerant … Recruiting
  2024-519310-31-00 Phase II 1 country Associazione Qol-One
• Improvement of MRI assessed cerebral Perfusion and oxygenation by luspatercept-induced Anemia Correction in non-transfusion dependent Thalas… Recruiting
  2023-504908-28-01 Phase III/IV 1 country Amsterdam UMC
• Phase 2 Study of Luspatercept in Adults and Adolescents with Alpha (α)-thalassemia Recruiting
  2022-502328-35-00 Phase II 2 countries Celgene Corp.
• A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to … Recruiting
  2024-515354-24-00 Phase I/II 2 countries Groupe Francophone Des Myelodysplasies
• Phase 2a Study of Luspatercept in Pediatric Participants With Beta (β)-Thalassemia Recruiting
  2022-502499-22-00 Phase II 3 countries Celgene Corp.
• A Phase 3b Study of BMS-986346 in Lower-risk Myelodysplastic Syndrome Participants Ended
  2023-504541-31-00 Phase III 7 countries Celgene Corp.
• 1L LUSPA VS ESA IN NTD LOW-RISK MDS PATIENTS Ended
  2022-500430-29-00 Phase III 8 countries Celgene Corp.
• A phase II, open-label, single arm study to evaluate the efficacy of Luspatercept in Erythropoiesis-stimulating agent naive lower-risk MDS p… Ended
  2024-516438-36-00 Phase II 1 country Universitaet Leipzig
• Assessment of effectiveness and safety of luspatercept in patients suffering from lower-risk myelodysplastic syndrome. Ended
  2024-515069-33-00 Phase III 3 countries GWT-Tud GmbH
• A study to evaluate the benefit and safety of Luspatercept (ACE-536) in adults with myeloproliferative neoplasm-associated myelofibrosis on … Ended
  2023-507890-17-00 Phase III 12 countries Celgene Corp.
• A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety of Luspatercept in subjects who have participated in other L… Ended
  2022-502498-40-00 Phase III 8 countries Celgene Corp.
• A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or inter… Ended
  2022-501485-22-00 Phase III 14 countries Celgene Corp.

Showing 1–14 of 14 trials